Topic: Growth Stocks

Medical stock expects more gain than pain from rapid growth by acquisition

Stryker Corp.

Recently Pat McKeough replied to a question from a Member of his Inner Circle regarding a fast-growing medical stock. This U.S. firm makes a wide range of medical products and continues to expand its product line by means of acquisitions.  

The company made its latest acquisition just two months ago, and Pat notes that Stryker Corp. is easily able to afford this purchase due to its high cash flow and low debt. Nonetheless, he adds, this heavy reliance on acquisition adds risk, and the company has had some quality control problems. 

Q: Pat: I would like your opinion on Stryker Corporation. I do hold it, but am thinking of adding to it. Thank you.


Where investors lose more money

“Overall, investors lose more money to conflicts of interest than to any other single risk. That’s not a comment about the average broker’s sense of ethics. It’s simply a matter of frequency of exposure times risk per exposure. For example, suppose you tell your broker that you have some money and you want to invest it aggressively…”
Whether you’re a Do-It-Yourself investor or have someone else handle your money, you will find many keys to building the retirement you want in Pat McKeough’s special report. Four decades of proven experience have gone into “Wealth Management and Retirement Planning”.

Read this FREE report >>

 


A: STRYKER CORP. (symbol SYK on New York; www.stryker.com) sells a range of medical products, including implants used in joint-replacement; surgical equipment; endoscopic devices (for looking inside the body); communications systems; patient-handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; and a range of other specialized medical gear.

The company has a history of using acquisitions to expand. Between 2012 and 2016, it spent $7.9 billion buying related firms.

Largely due to those new operations, Stryker’s revenue rose 30.8%, from $8.7 billion in 2012 to $11.3 billion in 2016.

However, its earnings fell 30.4%, from $3.39 a share (or a total of $1.3 billion) in 2012 to $1.34 a share (or $515 million) in 2014. That’s due to higher expenses related to the recall of certain products. Earnings then improved to $3.78 a share (or $1.4 billion) in 2015, and reached $4.35 a share (or $1.6 billion) in 2016. Stryker spends around 6% of its revenue on research.

In the quarter ended September 30, 2017, sales rose 6.1%, to $3.0 billion from $2.8 billion a year earlier. If you exclude the contribution of new businesses and exchange rates, sales improved 5.5% in the quarter.

If you exclude unusual items, earnings jumped 9.9%, to $578 million from $526 million. Due to slightly more shares outstanding, earnings per share gained 9.4%, to $1.52 from $1.39.

Growth stocks: U.S. approval for newly-acquired spinal implant expected soon

Stryker continues to use acquisitions to expand. In October 2017, it acquired 50.3% of VEXIM, a French company that makes spinal repair devices. Its main product is SpineJack, an expandable implant. Stryker expects regulators will approve SpineJack for sale in the U.S. in the next few months.

The company paid 183 million euros (about $212 million U.S.) for that stake. It plans to acquire the remaining shares in VEXIM by the end of 2017.

Stryker can easily afford this purchase. As of September 30, 2017, it held cash and investments of $2.7 billion. Its long-term debt of $6.6 billion is just 11% of its market cap.

The company expects to earn $6.45 to $6.50 a share for all of 2017. The stock, which has gained 39% in the past year, trades at 24.1 times the midpoint of that range. The $1.70 dividend yields 1.1%.

Uncertainty over the future of the U.S. Affordable Care Act (also known as Obamacare) adds risk to most medical products companies. Ongoing quality-control problems and costs related to product recalls are another risk factor for Stryker, in particular. Still, the company serves a growing market fuelled by the needs of aging baby boomers.

Inner Circle recommendation: Stryker Corporation is okay to hold.

For our recent report on a Canadian marijuana stock with a big deal in its pocket, read Aphria soars on marijuana sales, Shoppers deal.

For our advice on how to make the best of growth stocks, read 3 Growth Investing Strategies: Two we like—and one we don’t.

Comments

Tell Us What YOU Think

You must be logged in to post a comment.

Please be respectful with your comments and help us keep this an area that everyone can enjoy. If you believe a comment is abusive or otherwise violates our Terms of Use, please click here to report it to the administrator.